Vermillion's Q2 Revenues Rise on Increased OVA1 Sales | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market that its second-quarter revenues increased 6 percent year over year as sales volume for its OVA1 flagship diagnostic test rose by the same percentage.

The Austin, Texas-based molecular diagnostics firm brought in total revenues of $321,000 for the three months ended June 30, compared to $304,000 for the second quarter of 2011. Its license revenues, collected from clinical lab firm Quest Diagnostics, were static year over year at $113,000, while its product revenues increased to $208,000 from $191,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.